To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors
Clinical trial NCT06948539 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06948539
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-01
- Primary completion
- 2026-10-01
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.